Blog, News, Companies, blood glucose meters, oral, Nasal, transdermal, insulin,type 2, pancreatic islet cells, Macular Edema, Ulcers, continuous glucose monitoring, HbA1c, hemoglobin A1C, oral anti-diabetic agent, data management system, Hypoglycemia, glucagon, therapeutic vaccine, peripheral neuropathy, Neuropathic pain, diabetes mellitus, type 1, foot ulcers, test strip, glycemic control, nephropathy, resistant, sensitizers, foot infections, sensor, retinopathy, non-invasive monitor...
August 23, 2007 - Teijin Pharma Limited ("Teijin") and Chugai Pharmaceutical Co., Ltd. ("Chugai") have concluded a collaboration agreement to develop 
an anti-diabetic drug ITM-077 (Ipsen development code: BIM 51077, Roche and Chugai development code: R1583) in Japan originated by Ipsen (stock code Euronext: IPN) ... Teijin's Press Release - Chugai's Press Release -
